Jefferies Reiterates Bullish Stance on Nektar Therapeutics (NKTR) Following Meetings
Tweet Send to a Friend
Jefferies analyst David Steinberg reiterated a Buy rating and $15 price target on Nektar Therapeutics (NASDAQ: NKTR) following investor meetings ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE